METHODS OF DETERMINING RISK OF ADVERSE OUTCOMES IN ACUTE MYELOID LEUKEMIA

摘要

Disclosed are methods of determining risk of adverse outcome in a subject diagnosed with acute myeloid leukemia or myelodysplastic syndrome syndrome. The methods comprise providing a sample comprising bone marrow cells and/or peripheral blood from a subject diagnosed with acute myeloid leukemia or myelodysplastic syndrome syndrome, sequencing at least one exon of DNMT3A comprised by the sample, and identifying mutations, if any, in the DNMT3A gene. The presence of one or more mutations in DNMT3A can indicate that the subject is at high risk for an adverse outcome.